Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
13 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
RheumaFinder from Gent, company number BE0801688964, closed financial year 2025 with a result of € -284,346 after tax. For that financial year RheumaFinder recorded a gross margin of € 72,669 and equity of € 364,098. Compared with financial year 2024, the result moved from € -16,541 to € -284,346. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
€ 364,098
▼ 34% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -284,346
▼ 1619 % more loss than in 2024
Profit after tax over the fiscal year.
€ 176,856
▲ 15% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -300,887.
People and assets in 2025
€ 257,836
▲ 290% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,395
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 375,211
▲ € 350,120 vs 2024
Loans from banks and other lenders, long and short.
€ 33,160
▲ 85% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 48,814
▲ 293% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 40,225 | € 72,669 | ▲ 81% |
| Profit after taxes | € -16,541 | € -284,346 | ▼ € 267,805 |
| Equity | € 548,451 | € 364,098 | ▼ 34% |
| Total debts | € 73,163 | € 575,002 | ▲ € 501,838 |
| Cash | € 153,955 | € 176,856 | ▲ 15% |
| Retained profit | € -16,541 | € -300,887 | ▼ € 284,346 |
| Bank debt | € 25,092 | € 375,211 | ▲ € 350,120 |
| Balance sheet total | € 621,614 | € 939,100 | ▲ 51% |
Key figures of RheumaFinder, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to RheumaFinder?
What happened at RheumaFinder in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- B4M BV stepped down as director. NBB
- Thomas Van Den Berghe stepped down as director. NBB
- Ceelen Consultancy stepped down as director. NBB
- Nicolaas Fosselle stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 284,346. Source: NBB ↗
- B4M BV became a director. NBB
- Ceelen Consultancy became a director. NBB
- New establishment in Gent. KBO
In short
From € 16,541 loss in 2024 to € 284,346 loss in 2025.
A new publication or filing at RheumaFinder? We notify you, reason included.
Follow RheumaFinderDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Novalis II comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
RheumaFinderThe shares are held by Novalis II (27.7%).
Directors
According to the 2025 annual accounts
Director · represented by Wim Van Criekinge
Also active at: DE WIMMEN, Novalis II General Partner
since 2025 · until 2031
Thomas Van Den Berghe
Director
since 2023 · until 2031
since 2023 · until 2031
since 2023 · until 2031
Shareholders
27.7%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Vlasgaardstraat 52
9000 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.
All companies at this address →Billie Bonkers
€ 1.8 million gross margin · 2025
Partago
€ -66,545 gross margin · 2022
WATT FACTORY
€ 264,159 gross margin · 2025
ZIGGU
€ 610,605 gross margin · 2025
Healthblocks
€ 48,718 gross margin · 2025
+8 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0801.688.964
- VAT number
- BE 0801.688.964
- Registered office
- Vlasgaardstraat 52, 9000 Gent
- Names & denominations
- RheumaFinder
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 May 2023
- Peppol
- Active · Active since 6 Mar 2025
- Activities · NACE
Ontwerpen van computerprogramma’s
Ontwerpen en programmeren van computerprogramma's
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten
Computerconsultancy-activiteiten
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied